159 related articles for article (PubMed ID: 31100677)
1. HQSAR and random forest-based QSAR models for anti-T. vaginalis activities of nitroimidazoles derivatives.
Veríssimo GC; Menezes Dutra EF; Teotonio Dias AL; de Oliveira Fernandes P; Kronenberger T; Gomes MA; Maltarollo VG
J Mol Graph Model; 2019 Jul; 90():180-191. PubMed ID: 31100677
[TBL] [Abstract][Full Text] [Related]
2. 2-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study.
Mandalapu D; Kushwaha B; Gupta S; Singh N; Shukla M; Kumar J; Tanpula DK; Sankhwar SN; Maikhuri JP; Siddiqi MI; Lal J; Gupta G; Sharma VL
Eur J Med Chem; 2016 Nov; 124():820-839. PubMed ID: 27643640
[TBL] [Abstract][Full Text] [Related]
3. 5-Nitroimidazole drugs effective against metronidazole-resistant Trichomonas vaginalis and Giardia duodenalis.
Upcroft JA; Dunn LA; Wright JM; Benakli K; Upcroft P; Vanelle P
Antimicrob Agents Chemother; 2006 Jan; 50(1):344-7. PubMed ID: 16377707
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in
Graves KJ; Novak J; Secor WE; Kissinger PJ; Schwebke JR; Muzny CA
Parasitology; 2020 Nov; 147(13):1383-1391. PubMed ID: 32729451
[TBL] [Abstract][Full Text] [Related]
5. Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates.
Goodhew EB; Secor WE
Sex Transm Infect; 2013 Sep; 89(6):479-84. PubMed ID: 23794105
[TBL] [Abstract][Full Text] [Related]
6.
Ghosh AP; Aycock C; Schwebke JR
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29439963
[TBL] [Abstract][Full Text] [Related]
7.
Mtshali A; Ngcapu S; Govender K; Sturm AW; Moodley P; Joubert BC
Microbiol Spectr; 2022 Aug; 10(4):e0091222. PubMed ID: 35863010
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp.
Upcroft JA; Campbell RW; Benakli K; Upcroft P; Vanelle P
Antimicrob Agents Chemother; 1999 Jan; 43(1):73-6. PubMed ID: 9869568
[TBL] [Abstract][Full Text] [Related]
9. Drug repositioning for novel antitrichomonas from known antiprotozoan drugs using hierarchical screening.
Meneses-Marcel A; Marrero-Ponce Y; Ibáñez-Escribano A; Gómez-Barrio A; Escario JA; Barigye SJ; Terán E; García-Jacas CR; Machado-Tugores Y; Nogal-Ruiz JJ; Arán-Redó VJ
Future Med Chem; 2018 Apr; 10(8):863-878. PubMed ID: 29589477
[TBL] [Abstract][Full Text] [Related]
10. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles.
Meingassner JG; Thurner J
Antimicrob Agents Chemother; 1979 Feb; 15(2):254-7. PubMed ID: 311617
[TBL] [Abstract][Full Text] [Related]
11. Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance.
Leitsch D; Kolarich D; Binder M; Stadlmann J; Altmann F; Duchêne M
Mol Microbiol; 2009 Apr; 72(2):518-36. PubMed ID: 19415801
[TBL] [Abstract][Full Text] [Related]
12. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure.
Bosserman EA; Helms DJ; Mosure DJ; Secor WE; Workowski KA
Sex Transm Dis; 2011 Oct; 38(10):983-7. PubMed ID: 21934577
[TBL] [Abstract][Full Text] [Related]
13. [In vitro susceptibility of Trichomonas vaginalis to metronidazole, ornidazole and proton pump inhibitors pantoprazole and esomeprazole].
Aksoy Gökmen A; Girginkardeşler N; Kilimcioğlu AA; Şirin MC; Özbilgin A
Mikrobiyol Bul; 2016 Jan; 50(1):133-9. PubMed ID: 27058337
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the antitrichomonal activity of 5-nitroimidazole derivatives by hydrogen peroxide.
Mattana A; Juliano C; Picci V; Franconi F; Cappuccinelli P
New Microbiol; 1993 Oct; 16(4):359-65. PubMed ID: 8264426
[TBL] [Abstract][Full Text] [Related]
15. Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis.
Jarrad AM; Debnath A; Miyamoto Y; Hansford KA; Pelingon R; Butler MS; Bains T; Karoli T; Blaskovich MA; Eckmann L; Cooper MA
Eur J Med Chem; 2016 Sep; 120():353-62. PubMed ID: 27236016
[TBL] [Abstract][Full Text] [Related]
16. Exploring novel pyrazole-nitroimidazole hybrids: Synthesis and antiprotozoal activity against the human pathogen trichomonas vaginalis.
Silva RC; De Freitas A; Vicente B; Midlej V; Dos Santos MS
Bioorg Med Chem; 2024 Mar; 102():117679. PubMed ID: 38461555
[TBL] [Abstract][Full Text] [Related]
17. 'In vitro' study of chemotherapeutic activity of sulphimidazole on some sensitive and metronidazole-resistant Trichomonas vaginalis strains.
Malagoli M; Rossi T; Baggio A; Zandomeneghi G; Zanca A; Casolari C; Castelli M
Pharmacol Res; 2002 Nov; 46(5):469-72. PubMed ID: 12419652
[TBL] [Abstract][Full Text] [Related]
18. The antimicrobial peptides LL-37, KR-20, FK-13 and KR-12 inhibit the growth of a sensitive and a metronidazole-resistant strain of Trichomonas vaginalis.
Ramírez-Ledesma MG; Rodríguez MC; Alva-Murillo N; Avila EE
Parasitol Res; 2022 Dec; 121(12):3503-3512. PubMed ID: 36171407
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hydrogen production in drug-resistant and susceptible Trichomonas vaginalis strains by a range of nitroimidazole derivatives.
Lloyd D; Yarlett N; Yarlett NC
Biochem Pharmacol; 1986 Jan; 35(1):61-4. PubMed ID: 3000386
[No Abstract] [Full Text] [Related]
20. New chemotherapeutic nitroheterocycles active against 5-nitroimidazole-resistant strains of trichomonads.
Meingassner JG; Nesvadba H; Mieth H
Arzneimittelforschung; 1981; 31(1):6-8. PubMed ID: 6971111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
